Iridex Corporation (Nasdaq: IRIX) announced the expansion of its EyeProGPO product offering to include its line of EndoProbe Handpieces, according to a press release issued July 20, 2026.

Through the agreement, more than 4,300 EyeProGPO members will have access to preferred pricing on Iridex EndoProbe Handpieces. The members include ophthalmology practices, ambulatory surgery centers, and hospitals across the United States.

EndoProbe Handpieces are single-use devices indicated for use with Iridex laser consoles for the treatment of retinal disorders in adult patients. The portfolio includes straight, angled, stepped-angled, illuminating, and adjustable models, with configurations available in 20G, 23G, and 25G, and select stepped designs that taper to 27G and 30G.

Illuminating models combine white-light illumination with laser delivery in a single handpiece. Adjustable models provide continuous fiber-optic angle adjustment to support access to the peripheral retina.

The addition builds on Iridex's existing EyeProGPO product offering, which includes the Iridex PASCAL laser platform, IQ 532 and IQ 577 Laser Consoles, OcuLight TX Laser Console, Cyclo G6 Laser Console, and the MicroPulse P3, G-Probe, and G-Probe Illuminate delivery devices.

"We are pleased to add Iridex EndoProbe Handpieces to our EyeProGPO product offering, giving members broader access to our retina laser systems and delivery devices," said Patrick Mercer, President and CEO of Iridex.